Literature DB >> 11384097

Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.

J L Jouve1, L Remontet, V Dancourt, C Lejeune, A M Benhamiche, J Faivre, J Esteve.   

Abstract

3 controlled cohorts of mass-screening for colorectal cancer using a biennial faecal occult blood (HemoccultII test on well-defined European populations have demonstrated a 14% to 18% reduction in specific mortality. We aimed to estimate the sensitivity (S) of this HemoccultII test and and also mean sojourn time (MST) from French colorectal mass-screening programme data. 6 biennial screening rounds were performed from 1988 to 1998 in 45 603 individuals aged 45-74 years in Saône-et-Loire (Burgundy, France). The prevalent/incidence ratio was calculated in order to obtain a direct estimate of the product S.MST. The analysis of the proportional incidence and its modelling was used to derive an indirect estimate of S and MST. The product S.MST was higher for males than females and higher for left colon than either the right colon or rectum. The analysis of the proportional incidence confirmed the result for subsites but no other significant differences were found. The sensitivity was estimated at 0.57 and the MST at 2.56 years. This study confirms that the sensitivity of the Hemoccult test is relatively low and that the relatively short sojourn time is in favour of annual screening. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Year:  2001        PMID: 11384097      PMCID: PMC2363664          DOI: 10.1054/bjoc.2001.1752

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Analysis of screening data: colorectal cancer.

Authors:  D Gyrd-Hansen; J Søgaard; O Kronborg
Journal:  Int J Epidemiol       Date:  1997-12       Impact factor: 7.196

2.  Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.

Authors:  N E Day; S D Walter
Journal:  Biometrics       Date:  1984-03       Impact factor: 2.571

3.  Estimating the sensitivity of a screening test.

Authors:  N E Day
Journal:  J Epidemiol Community Health       Date:  1985-12       Impact factor: 3.710

Review 4.  Screening for colorectal cancer using the faecal occult blood test, hemoccult.

Authors:  B P Towler; L Irwig; P Glasziou; D Weller; J Kewenter
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test.

Authors:  S M Moss; J D Hardcastle; D A Coleman; M H Robinson; V C Rodrigues
Journal:  Int J Epidemiol       Date:  1999-06       Impact factor: 7.196

6.  Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.

Authors:  G Launoy; T C Smith; S W Duffy; V Bouvier
Journal:  Int J Cancer       Date:  1997-10-09       Impact factor: 7.396

7.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

8.  Participation in faecal occult blood screening for colorectal cancer in a well defined French population: results of five screening rounds from 1988 to 1996.

Authors:  M A Tazi; J Faivre; F Dassonville; J Lamour; C Milan; G Durand
Journal:  J Med Screen       Date:  1997       Impact factor: 2.136

9.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

10.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

View more
  5 in total

Review 1.  Gastroscopy following a positive fecal occult blood test and negative colonoscopy: systematic review and guideline.

Authors:  Johane Allard; Roxanne Cosby; M Elisabeth Del Giudice; E Jan Irvine; David Morgan; Jill Tinmouth
Journal:  Can J Gastroenterol       Date:  2010-02       Impact factor: 3.522

2.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.

Authors:  Ann G Zauber; Sidney J Winawer; Michael J O'Brien; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Benjamin F Hankey; Weiji Shi; John H Bond; Melvin Schapiro; Joel F Panish; Edward T Stewart; Jerome D Waye
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

3.  Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.

Authors:  Wenying Zheng; Carolyn M Rutter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-21       Impact factor: 4.254

4.  Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.

Authors:  Grace Hui-Min Wu; Yi-Ming Wang; Amy Ming-Fang Yen; Jau-Min Wong; Hsin-Chih Lai; Jane Warwick; Tony Hsiu-Hsi Chen
Journal:  BMC Cancer       Date:  2006-05-24       Impact factor: 4.430

5.  Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.

Authors:  G Castiglione; C B Visioli; S Ciatto; G Grazzini; A G Bonanomi; T Rubeca; P Mantellini; M Zappa
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.